https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png
0
0
Webadm
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png
Webadm2026-09-11 23:59:322026-09-14 10:00:33Queen Square MND Centre 7th Annual ALS/MND International Symposium
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png
0
0
Webadm
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png
Webadm2026-09-10 23:59:532026-09-11 14:03:01My Name’5 Doddie Foundation’s Discovery Network Showcase 2026
https://www.nrgtherapeutics.com/wp-content/uploads/2026/09/LP_090926.jpg
720
1280
Webadm
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png
Webadm2026-09-09 10:05:482026-09-14 10:06:34ALS Drug NRG5051 Targets Mitochondrial Pore to Protect Neurons
https://www.nrgtherapeutics.com/wp-content/uploads/2026/09/LT_080926.jpg
800
1200
Webadm
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png
Webadm2026-09-08 10:04:432026-09-14 10:10:15New ALS drug data reveal a mitochondrial fix
https://www.nrgtherapeutics.com/wp-content/uploads/2026/09/BioUK_040926.png
720
1200
Webadm
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png
Webadm2026-09-04 10:03:522026-09-14 10:04:37Coulter Partners places Claus Sundgreen, M.D. as Chief Medical Officer at NRG Therapeutics
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png
0
0
Webadm
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png
Webadm2026-08-26 23:59:442026-09-11 14:22:41ALS Nexus Conference 2026
https://www.nrgtherapeutics.com/wp-content/uploads/2026/09/P_250826.jpg
650
1024
Webadm
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png
Webadm2026-08-25 10:03:042026-09-14 10:07:30NRG5051 Targets mPTP Through Novel NLRX1 Mechanism in ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/09/DDW_250826.jpg
533
800
Webadm
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png
Webadm2026-08-25 10:02:072026-09-14 10:02:47New drug displays anti-inflammatory and neuroprotective effects in ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png
0
0
Webadm
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png
Webadm2026-08-24 09:01:082026-09-14 09:02:17NRG Therapeutics Presents Data on Lead Clinical Asset NRG5051 Confirming Novel Disease-Modifying Approach to ALS© NRG Therapeutics
